“…Little is known how complex formation with its target antigen HER2 affects these modifications. Modifications in the CDRs of trastuzumab were thus compared between the free antibody and the trastuzumab–HER2 complex when stressed under physiological conditions at 37°C. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Breast cancer is a heterogeneous disease with overexpression of several receptors, such as human epidermal receptor 2 (HER2), which is a prognostic and predictive biomarker for treatment with the anti-HER2 monoclonal antibody trastuzumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Resistance to HER2-targeted therapeutics remains a significant clinical problem in HER2+ breast cancer patients with advanced disease. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: HER2 is one of the most extensively studied oncogenes in solid tumors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Breast cancers that are HER2 positive account for 15 to 20% of all breast cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Metastatic HER2 + breast cancer is an expanding area of drug development and research, with three new drugs approved in 2020 alone. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SIMPLE SUMMARY: Brain metastases (BMs) are common among patients with advanced HER2 breast cancer. The recent introduction of systemic therapy with central nervous system activity as well as the wider use of brain stereotactic radiotherapy (SRT) are contributing to improving the outcomes for these patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Methods: This investigation uses publicly available genomic data to examine ER-positive/HER2-negative or luminal breast cancers with high mutation numbers and compare them with cancers of the same subtype and low mutation numbers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In the phase III PHOEBE trial, treatment with pyrotinib plus capecitabine significantly improved overall survival compared with lapatinib plus capecitabine in patients with previously treated HER2-positive metastatic breast cancer.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Through database analyses, we identified EGFR/HER2 signaling to be essential in human cancers with high TAZ activity. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MFCH401, a 9-mer specific peptide fragment (DTILWKDIF) in the extracellular domain of the HER2 protein, is an attractive epitope for developing anti-HER2 cancer vaccines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here, the progress in the preparation of high efficiency hydrogen evolution reaction (HER) catalyst is reported. The support material is based on a polyhexaphenylbenzene material with intrinsic holes, which heals into carbon materials upon heating. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Pathological evidence showed human epidermal growth factor receptor 2 (HER2)(3+). Abdominal computed tomography revealed a mass in the gastric body, gastroscopic biopsy showed HER2(3+). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Systemic anti‐HER2 therapy following a diagnosis of BrM improves outcomes. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…LAYMAN SUMMARY: HER2 is an oncogenic driver in a subset of breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth factor receptor 2 (HER2) is a highly expressed tumor marker in epithelial ovarian cancer, and its overexpression is considered to be a potential factor of poor prognosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This review provides an updated account on the current methods, principles and mechanism of action of therapies for the detection of molecular markers of therapeutic importance in the prognosis of breast cancer progression and recurrence, which includes estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor2 (HER2). Indeed, hormone-receptors namely, ER, PR, proto-oncogene HER2 are the basic molecular markers that are recognized and established prognostic factors and predictors of response, for therapeutic practice. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso